Provided by Tiger Fintech (Singapore) Pte. Ltd.

Incyte

60.55
-0.0500-0.08%
Post-market: 60.50-0.0500-0.08%19:05 EDT
Volume:1.70M
Turnover:102.67M
Market Cap:11.72B
PE:403.67
High:60.81
Open:60.15
Low:59.10
Close:60.60
Loading ...

Company Profile

Company Name:
Incyte
Exchange:
NASDAQ
Establishment Date:
1991
Employees:
2617
Office Location:
1801 Augustine Cut-Off,Wilmington,Delaware,United States
Zip Code:
19803
Fax:
- -
Introduction:
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Directors

Name
Position
Herve Hoppenot
President and Chief Executive Officer and Chairman of the Board
Edmund P. Harrigan
Director
Jacqualyn A. Fouse
Director
Jean Jacques Bienaime
Director
Julian C. Baker
Director
Katherine A. High
Director
Otis W. Brawley
Director
Paul J. Clancy
Director
Susanne Schaffert
Director

Shareholders

Name
Position
Herve Hoppenot
President and Chief Executive Officer and Chairman of the Board
Christiana Stamoulis
Executive Vice President and Chief Financial Officer
Lee Heeson
Executive Vice President, Incyte International
Matteo Trotta
Executive Vice President, General Manager, Dermatology US
Michael Morrissey
Executive Vice President and Head of Global Technical Operations
Mohamed Issa
Executive Vice President, Head of US Oncology
Pablo J. Cagnoni
President and Head of Research and Development
Paula J. Swain
Executive Vice President, Human Resources
Sheila Denton
Executive Vice President, General Counsel and Corporate Secretary
Steven Stein
Executive Vice President and Chief Medical Officer
Thomas Tray
Vice President and Chief Accounting Officer
Vijay Iyengar
Executive Vice President, Global Strategy and Corporate Development